Dr. MacLean and Dr. Jiang have found that spermine and spermidine are novel therapeutics for the treatment of Homocystinuria. In-vivo studies have demonstrated low spermine and spermidine levels in mouse models with HCU phenotype. The inventors believe that spermine and spermidine supplementation may provide clinical benefit in patients with HCU.